How 5 Diseases Respond Better To Cannabis Than Prescription Drugs
The results of testing of cannabis on various diseases has resulted in some significant findings. As research continues, it is possible that even more diseases will be added to this list.
Cannabinoids, the active components of marijuana, inhibit tumor growth and also kill cancer cells. Tetrahydrocannabinol (THC), the principal psychoactive constituent (or cannabinoid) of the cannabis plant, targets cannabinoid receptors similar in function to endocannabinoids, which are cannabinoids that are naturally produced in the body and activate these receptors.
Researchers have now found that cannabidiol has the ability to ‘switch off’ the gene responsible for metastasis in an aggressive form of cancer. Importantly, this substance does not produce the psychoactive properties of the cannabis plant.
A Spanish team, led by Dr Manuel Guzmon, wanted to see whether they could prevent a form of cancer (glioblastoma multiforme) from growing by cutting off its blood supply. Glioblastoma multiforme is one of the most difficult cancers to treat – it seldom responds to any medical intervention, especially conventional methods which poisoning and primatively destroy cells such as radiotherapy, chemotherapy and surgery.
Genes associated with blood vessel growth in tumors through the production of a chemical called vascular endothelial growth factor (VEGF) have their activity reduced when exposed to cannabinoids.
Cannabinoids halt VEGF production by producing Ceramide. Ceramide controls cell death.
Dr Manuel Guzmon tested a cannabinoid solution of patients had glioblastoma multiforme and had not responded to chemotherapy, radiotherapy or surgery. The scientists took samples from them before and after treating them with a cannabinoids solution – this was administered directly into the tumor.
Amazingly, both patients experienced reduced VEGF levels in the tumor as a result of treatment with cannabinoids.
A study published in the July 2002 edition of the medical journal Blood, which found that THC and some other cannabinoids produced “programmed cell death” in different varieties of human leukemia and lymphoma cell lines, thereby destroying the cancerous cells but leaving other cells unharmed.
A study published in a 1975 edition of the Journal of the National Cancer Institute, which showed that THC slowed the growth of lung cancer, breast cancer and virus-induced leukemia in rats.
Titled Antineoplastic activity of cannabinoids, this study was funded by the US National Institute of Health, and performed by researchers at the Medical College of Virginia. Despite the promising results, no further research was made, and the study has essentially disappeared from the scientific literature.
A 1994 study, which documented that THC may protect against malignant cancers, and which was buried by the US government. The $2 million study, funded by the US Department of Health and Human Services, sought to show that large doses of THC produced cancer in rats. Instead, researchers found that massive doses of THC had a positive effect, actually slowing the growth of stomach cancers. The rats given THC lived longer than their non-exposed counterparts.
he study was unpublished and the results hidden for almost three years, until it was finally leaked to the media in 1997. (CC#17, THC for tumors).
2. Fibromyalgia (FM)
More and more patients with FM are finding effective relief from cannabis.
So say the results of a recent online survey of over 1,300 subjects conducted by The National Pain Foundation and NationalPainReport.com. Among those surveyed, 379 subjects said that they had used cannabis therapeutically. Sixty-two percent of them rated the substance to be “very effective” in the treatment of their condition.
By comparison, among those FM patients who had used Cymbalta (Duloxene), only eight percent rated the drug as “very effective,” and 60 percent said it did “not work at all.” Among those who had used Lyrica (Pregabalin), ten percent said that drug was “very effective,” versus 61 percent who reported no relief. Among those who had used Savella (Milnacipran), ten percent rated the drug as effective, and 68 percent said it was ineffective.
Commenting on the survey results, Dr. Mark Ware — associate professor in family medicine and anesthesia at McGill University in Montreal — told the National Pain Report, “We desperately need someone to step up and explore this potential for the efficacy of cannabis.”
Ware, whose own clinical research has demonstrated inhaled pot’s efficacy in subjects with hard-to-treat refractory pain, added: “The scientific rationale is there. There are some early preliminary, proof-of-concept clinical trials that demonstrate cannabis may be effective. Now your study adds additional weight that patients are reporting that cannabis may be better than the existing therapies. I think that this really should provide incentives for researchers to take a hard look at clinical trials to really explore that in much more detail.”
Some investigators already have. In 2006, German scientists reportedthat the administration of oral THC significantly reduced both chronic and experimentally induced pain in patients with fibromyalgia. Subjects in the trial were administered daily doses of 2.5 to 15 mg of THC, but received no other pain medication during the study. Among those participants who completed the trial, all reported significant reductions in daily pain and electronically induced pain.
More recently, Spanish researchers assessed the use of cannabis treatment of Fibromyalgia. A cursory review of the results indicates why so many FM patients are preferring pot over pills.
Investigators reported, “The use of cannabis was associated with beneficial effects on some FM symptoms. … After two hours of cannabis use, VAS (visual analogue scales) scores showed a statistically significant reduction of pain and stiffness, enhancement of relaxation, and an increase in somnolence and feeling of well being.”
By far the most common approach to treating epilepsy is to prescribe antiepileptic drugs. Commonly prescribed drugs include clonazepam, phenobarbital, and primidone. Some relatively new epilepsy drugs includetiagabine, gabapentin, topiramate, levetiracetam, and felbamate. Many medications amplify side effects such as fatigue and decreased appetite. Epilepsy medication also may predispose people to developing depression or psychoses.
Several lines of evidence now suggest that cannabinoid compounds are anticonvulsant and empirical evidence in many children is establishing conclusive evidence that cannabinoid therapy may be the most effective treatment available for epileptics.
In “The Endogenous Cannabinoid System Regulates Seizure Frequency and Duration in a Model of Temporal Lobe Epilepsy”, Robyn Wallace explained that the data not only shows the anticonvulsant activity of exogenously applied cannabinoids but also suggests that endogenous cannabinoid tone modulates seizure termination and duration through activation of the CB1 receptor. By demonstrating a role for the endogenous cannabinoid system in regulating seizure activity, these studies define a role for the endogenous cannabinoid system in modulating neuroexcitation. The endogenous cannabinoid system thus provides on-demand protection against acute excitotoxicity in central nervous system neurons.
Anti-convulsant drugs have potentially serious side-effects, including bone softening, reduced production of red blood cells, swelling of the gums, and emotional disturbances. Other occasional effects include uncontrollable rapid eye movements, loss of motor co-ordination, coma and even death. In addition, these medications are far from ideal in that they only completely stop seizures in about 60% of patients. Large amounts of anecdotal reports and patient case studies indicate the assistance of cannabis in controlling seizures. Cannabis analogues have been shown to prevent seizures. Patients report that they can wean themselves off prescription drugs, and still not experience seizures if they have a regular supply of cannabis.
The British company, GW Pharmaceuticals pursued advanced clinical trials for the world’s first pharmaceutical developed from raw marijuana instead of synthetic equivalents. In response to urgent need expressed by parents of children with intractable epilepsy, the U.S. Food and Drug Administration is now allowing Investigational studies of purified CBD (cannabidiol) for seizures.
Ben Whalley and colleagues at the Center for Integrative Neuroscience and Neurodynamics, University of Reading, using mouse models of epilepsy, established safety and showed that CBD and another cannabinoid, CBDV, exert anti-seizure and anti-inflammatory effects. This research came to the attention of families in the US who had loved ones with epilepsy.
The British Medical Association has stated that cannabis may prove useful as an ‘adjunctive therapy’ for patients who cannot be kept satisfactorily free of seizures on current medications. Likewise, the National Institutes of Health workshop considered that this is ‘an area of potential value’, based largely on animal research showing anticonvulsant effects.
Charlotte’s Web is a sativa marijuana strain that has gained popularity as a good option for treating seizures as well as a range of other medical conditions. This medical potency is due to its high-CBD content, which was specifically cultivated by Colorado breeders The Stanley Brothers for a young epileptic patient named Charlotte. This strain is effective with little to no psychoactive effects, making it great for those who don’t want their medication to affect their daily tasks.
See full article here at http://www.fuelwellness.com/how-5-diseases-respond-better-to-cannabis-than-prescription-drugs/2/